DiMarco Anthony F, Kowalski Krzysztof E, Hromyak Dana R, Geertman Robert T
J Spinal Cord Med. 2014 Jul;37(4):380-8. doi: 10.1179/2045772313Y.0000000152. Epub 2013 Nov 26.
To determine the long-term effects of the cough stimulation system.
Nonrandomized clinical trial of subjects using the study device well beyond the period of close follow-up.
Use of the study device in the home setting.
Subjects (N = 10) implanted with the device for a minimum of 2 years (mean 4.6 ± 0.6 years).
Application of daily stimulation.
Airway pressure generation and other clinical assessments including ease in raising secretions, life quality, caregiver support, and incidence of respiratory tract infections were measured at 1 year and mean 4.6 years after implantation.
Each subject continued to use the device on a regular basis. During SCS, mean maximum airway pressures were 103.1 ± 20.4 and 107.7 ± 23.0 cm H₂O at the 1-year and mean 4.6-year follow-up points, respectively (P < 0.05 compared with pre-implant and not significantly different (NS) compared with 1-year follow-up). Benchmarks related to ease in raising secretions and improvements in life quality related to respiratory care were maintained at the mean 4.6 year follow-up. The need for trained caregivers to provide other means of secretion management remained significantly below the pre-implant values (P < 0.05). The incidence of acute respiratory tract infections remained low at 0.2 ± 0.1 events/year, which is significantly below the pre-implant value of 1.4 ± 0.3 events/year (P < 0.05).
Subjects continued to use the system on a long-term basis beyond the period of close follow-up and to continued derive significant clinical benefits.
确定咳嗽刺激系统的长期效果。
对使用研究设备时间远超密切随访期的受试者进行非随机临床试验。
在家庭环境中使用研究设备。
10名受试者植入该设备至少2年(平均4.6±0.6年)。
每日进行刺激。
在植入后1年和平均4.6年时测量气道压力产生情况以及其他临床评估指标,包括咳痰难易程度、生活质量、护理人员支持情况和呼吸道感染发生率。
每位受试者继续定期使用该设备。在咳嗽刺激期间,1年随访点和平均4.6年随访点的平均最大气道压力分别为103.1±20.4 cmH₂O和107.7±23.0 cmH₂O(与植入前相比P<0.05,与1年随访相比无显著差异)。在平均4.6年随访时,与咳痰难易程度相关的基准以及与呼吸护理相关的生活质量改善情况得以维持。训练有素的护理人员提供其他分泌物管理方法的需求仍显著低于植入前值(P<0.05)。急性呼吸道感染发生率保持在较低水平,为0.2±0.1次/年,显著低于植入前的1.4±0.3次/年(P<0.05)。
受试者在密切随访期之后仍长期使用该系统,并持续获得显著的临床益处。